Purified mesenchymal stem cell exosomes and uses thereof
AssigneeChildren's Medical Center Corporation
InventorsS. Alexander Mitsialis, Stella Kourembanas
Life of this patent
Estimating the term…
Abstract
Provided herein are isolated exosomes from mesenchymal stem cells (MSC). Such isolated exosomes are substantially CT free of contaminants and are therapeutically active in treating various diseases (e.g., lung diseases such as BPD). The isolated MSC exosomes are identified by one or more protein markers described herein. Methods of purifying such MSC exosomes are also provided.
Claims53
An isolated mesenchymal stem cell (MCS) exosome, wherein:
- (i) the isolated MSC exosome comprises one or more markers selected from the group consisting of FLT1, PLAUR, MME, CDH2, SLC16A3, CDH13, ITGB5, ITGA11, APP, GPC6, IGSF8, IRP2, TSPAN9, DAG1, SLC38A2, SLC12A8, GJA1, ITGA1, PLXNB2, SLC16A1, and PROCR;
- (ii) the isolated MSC exosome comprises one or more markers that is enriched compared to a fibroblast exosome, the one or more markers selected from the group consisting of:
- PTk7, CD109, SLC1A5, ITGA3, ITGA2, BSG, DPP4, ATP1A1, FAP, VASN, IGF2R, and CD82;
- and/or
- (iii) the isolated MSC exosome comprises one or more markers that is enriched compared to a fibroblast exosome, the one or more markers selected from the group consisting of RCN1, RAP1B, GDF15, FLT1, OLFML3, PLOD2, PSMA4, PAPPA, INHBA, SPOCK1, HSPB1, LOXL4, POLD3, CALU, IGFBP4, C4B, TINAGL1, SULF1, TPM3, AHNAK, CALR, RRAS2, PFKP, and COL16A1.
A method of isolating a mesenchymal stem cell (MSC) exosome, the method comprising fractionating MSC-conditioned media using an iodixanol (IDX) cushion gradient and collecting a fraction that is substantially free of non-exosomal protein contaminants.
Dependencies are inferred from the claim text.